GC Genome Posts 31.5 Billion Won Revenue and 1.2 Billion Won Operating Profit in First Year of Listing... New Business Drives Return to Profitability

GCC Genome announced on the 19th that it successfully turned a profit last year, recording annual revenue of 31.5 billion won and operating profit of 1.2 billion won, according to its preliminary earnings disclosure. Revenue increased by 5.6 billion won (22%) compared to the previous year's 25.9 billion won, while operating profit improved by 2.5 billion won, shifting from a 1.2 billion won operating loss the previous year to a profit.

This improvement in performance was driven by balanced sales growth across all testing segments, including obstetrics, oncology, rare genetic diseases, and health checkups, with high growth in the obstetrics and health screening divisions-core new businesses-playing a key role. According to the company, the number of 'iCancerSearch' health screening tests increased from 900 in 2024 to 5,100 in 2025, and the core obstetric test, the non-invasive prenatal test (G-NIPT), also rose from 18,000 to 25,200 cases during the same period.

On the profitability front, economies of scale were achieved as the number of test requests increased. The higher testing volume eased the burden of fixed costs such as labor and equipment, and the cost-to-sales ratio dropped by 1 percentage point year-on-year, which contributed to the turnaround in profitability.

Non-operating factors also supported the results. The company secured about 43 billion won in public offering funds through its initial public offering (IPO) in June last year, which led to increased interest income and higher net financial gains. Its cash holdings also grew from 6.5 billion won the previous year to 40.1 billion won. In addition, the increased value of its equity holdings following the merger of its affiliates, Zenith Health and GC Labtech, was reflected as a rise in other income.

GCC Genome plans to sustain its revenue growth and profitability improvement by expanding major testing products both domestically and internationally.